Search results for "Uterotonic"

showing 3 items of 3 documents

Successful treatment of life-threatening bleeding after cesarean section with recombinant activated factor VII.

2006

Hemorrhagic shock developed in a 29-year-old nullipara without coagulopathy after emergency caesarean section. Treatment with uterotonic drugs, prostaglandins, and conservative procedures with transfusion of packed red cells and fresh-frozen plasma failed to control the diffuse vaginal and uterine bleeding. Finally an intravenous bolus injection of 90 μg/kg recombinant activated factor VII (rFVIIa, NovoSeven®, Novo Nordisk A/S, Bagsvaerd, Denmark), was given and showed success within 20 minutes after administration, without any side effects.

Adultmedicine.medical_specialtyPacked Red CellsCritical IllnessUterotonicFactor VIIa030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicinelawPregnancyActivated factor VIImedicineCoagulopathyHumans030212 general & internal medicinepostpartum bleedingbusiness.industryCesarean SectionPostpartum HemorrhageUterine bleedingHematologyGeneral MedicineFactor VIImedicine.diseaseRecombinant ProteinsSurgeryTreatment OutcomeAnesthesiaHemorrhagic shockRecombinant DNAFemalebusinessClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
researchProduct

Oxytocin receptor ligands: a survey of the patent literature

2008

Background: Oxytocin is produced primarily in hypothalamic neurons and is secreted from the posterior pituitary gland into the circulation in response to stimuli such as suckling, parturition, or stress. Oxytocin functions as an essential component in milk ejection and is among the most potent uterotonic substances known. The oxytocin receptor system supports physiological processes associated with reproduction at several levels. Objective: To characterize and evaluate oxytocin receptor ligands for therapeutic applications. Methods: Analysis of oxytocin analogs and nonpeptide oxytocin receptor ligands, and major applications of these substances. Results/conclusion: Oxytocin receptor ligands…

Pharmacologyendocrine systemmedicine.medical_specialtyUterotonicGeneral MedicineBiologyOxytocin receptorOxytocin AntagonistIn vitromedicine.anatomical_structureEndocrinologyOxytocinPosterior pituitaryInternal medicineLactationDrug Discoverymedicinehormones hormone substitutes and hormone antagonistsVasopressin receptormedicine.drugExpert Opinion on Therapeutic Patents
researchProduct

Postpartum Hemorrhage: Conservative Treatments

2023

Postpartum hemorrhage (PPH) is an obstetric emergency representing the first cause of obstetric mortality and a frequent cause of severe maternal morbidity. It can complicate vaginal or cesarean deliveries and accounts for 25% of all maternal deaths worldwide, as reported by the World Health Organization (WHO). Primary PPH is defined as blood loss from the genital tract of at least 500 ml after vaginal or 1000 ml following cesarean delivery within 24 h postpartum, whereas secondary PPH is defined as any significant bleeding from the birth canal occurring between 24 h and 12 weeks postnatally. Uterine atony is reported as the main cause of PPH and accounts for 75%–90% of primary PPH. When ut…

Postpartum hemorrhageUterotonic agentUterine tamponade procedureVascular ligation.Selective arterial embolizationUterine compression sutureUterine atonySettore MED/40 - Ginecologia E Ostetricia
researchProduct